Related Experiment Videos
Environmental photodegradation of mefenamic acid
Jeffrey J Werner1, Kristopher McNeill, William A Arnold
1Water Resources Science Program, University of Minnesota, 1985 Buford Avenue, St. Paul, MN 55108, USA.
Chemosphere
|February 3, 2005
Summary
Mefenamic acid, a common anti-inflammatory drug, undergoes slow direct photolysis in water. Photosensitization by dissolved organic matter significantly enhances its degradation, suggesting combined processes control its environmental persistence.
Area of Science:
- Environmental Chemistry
- Photochemistry
- Pharmaceutical Pollution
Background:
- Pharmaceuticals and personal care products (PPCPs) are emerging environmental pollutants.
- Photolysis is a key degradation pathway for PPCPs in surface waters.
- Mefenamic acid (MEF) is a widely used non-steroidal anti-inflammatory drug (NSAID).
Purpose of the Study:
- To investigate the direct photolysis and photosensitization of mefenamic acid in aquatic environments.
- To elucidate the mechanisms of photosensitization involving dissolved organic matter.
- To assess the environmental persistence of mefenamic acid.
Main Methods:
- Direct photolysis quantum yield measurements.
- Photosensitization experiments using natural waters and model photosensitizers (fulvic acid, acetophenones, perinaphthenone).
- Quenching, sparging, and light-filtering techniques to identify reaction pathways.
Main Results:
- Direct photolysis quantum yield of mefenamic acid was low (1.5+/-0.3x10(-4)).
- Significant photosensitization was observed with dissolved organic matter and model sensitizers.
- Evidence suggests reaction with excited triplet-state dissolved organic matter is the primary photosensitization mechanism.
Conclusions:
- Mefenamic acid photodegradation in natural waters is influenced by both direct photolysis and indirect photosensitization.
- The persistence of mefenamic acid is controlled by a combination of these processes.
- Understanding these pathways is crucial for assessing the environmental fate of NSAIDs.